MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhep.2014.08.021

Медицинская библиотека · Journal of hepatology · 2014

Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.

Marcellin Patrick, Wursthorn Karsten, Wedemeyer Heiner, Chuang Wan-Long, Lau George, Avila Claudio, Peng Cheng-Yuan, Gane Edward, Lim Seng Gee, Fainboim Hugo, Foster Graham R, Safadi Rifaat, Rizzetto Mario, Manns Michael, Bao Weibin, Trylesinski Aldo, Naoumov Nikolai

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND & AIMS: This study investigated the antiviral efficacy and safety of telbivudine in combination with pegylated interferon (PegIFN) alpha-2a in chronic hepatitis B (CHB) patients.

METHODS

This was a randomized, open-label, multicentre study, in treatment-naïve patients with HBeAg-positive CHB, comparing the efficacy and safety of telbivudine in combination with PegIFN alpha-2a with telbivudine monotherapy and PegIFN alpha-2a monotherapy. The study was terminated early due to increased rates of peripheral neuropathy in the combination-therapy group.

RESULTS

Of the 159 patients randomized (from 300 planned) 50 were assigned to combination therapy, 55 to telbivudine, 54 to PegIFN, and 110 (18, 49, and 43, respectively) reached week 24. Peripheral neuropathy occurred in 7/50, 1/54, and 0/54 patients in the three groups of safety populations, respectively. No relationship between the occurrence of peripheral neuropathy and other variables (e.g., pharmacokinetic data, treatment efficacy, ALT levels, creatine kinase elevations) were observed. At week 24, undetectable HBV DNA (<300 copies/ml) was achieved by 71% (12/17), 35% (17/48), and 7% (3/42) of patients, with available data receiving combination therapy, telbivudine monotherapy and PegIFN monotherapy, respectively (p = 0.022 for combination therapy vs. telbivudine; p<0.0001 for combination therapy vs. PegIFN).

CONCLUSIONS

Combination therapy carried an increased risk of peripheral neuropathy. Despite the rapid and profound reductions in HBV DNA levels, combination therapy with telbivudine and PegIFN should not be used.

Для цитирования: Marcellin Patrick, Wursthorn Karsten, Wedemeyer Heiner, Chuang Wan-Long, Lau George, Avila Claudio, Peng Cheng-Yuan, Gane Edward, Lim Seng Gee, Fainboim Hugo, Foster Graham R, Safadi Rifaat, Rizzetto Mario, Manns Michael, Bao Weibin, Trylesinski Aldo, Naoumov Nikolai. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.. Journal of hepatology. 2014. DOI: 10.1016/j.jhep.2014.08.021.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.